A novel large deletion of the ICR1 region including H19 and putative enhancer elements

BMC Medical Genetics

Karin Buiting³  Andrea Riccio¹  Susanne Bens⁶  Hermann-Josef Lüdecke³  Flavia Cerrato¹  Christina Kanaka-Gantenbein⁵  Evangelia Lykopoulou⁵  Christalena Sofocleous²  Deniz Kanber³  Stella Amenta⁴  Helen Fryssira² 

[1] Institute of Genetics and Biophysics A. Buzzati-Traverso, CNR, DiSTABiF, 2nd University of Naples, Naples, Italy;Aghia Sophia Children’s Hospital, University of Athens Medical School, Athens 11527, Goudi, Greece;Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany;Mitera Maternity Hospital, Athens, Greece;First Pediatric Clinic, Aghia Sophia” Children’s Hospital, University of Athens School of Medicine, Athens, Greece;Institute of Human Genetics, University Hospital Schleswig-Hostein Campus Kiel/Christian-Albrechts University Kiel, Kiel, Germany

关键词: DNA methylation;    Imprinting disorders;    Genomic imprinting;    Beckwith-Wiedemann syndrome;   

Others  :  1180311
DOI  :  10.1186/s12881-015-0173-2

 received in 2014-11-09, accepted in 2015-04-22,  发布年份 2015

【 摘 要 】

Background

Beckwith-Wiedemann syndrome (BWS) is a rare pediatric overgrowth disorder with a variable clinical phenotype caused by deregulation affecting imprinted genes in the chromosomal region 11p15. Alterations of the imprinting control region 1 (ICR1) at the IGF2/H19 locus resulting in biallelic expression of IGF2 and biallelic silencing of H19 account for approximately 10% of patients with BWS. The majority of these patients have epimutations of the ICR1 without detectable DNA sequence changes. Only a few patients were found to have deletions. Most of these deletions are small affecting different parts of the ICR1 differentially methylated region (ICR1-DMR) removing target sequences for CTCF. Only a very few deletions reported so far include the H19 gene in addition to the CTCF binding sites. None of these deletions include IGF2.

Case presentation

A male patient was born with hypotonia, facial dysmorphisms and hypoglycemia suggestive of Beckwith-Wiedemann syndrome. Using methylation-specific (MS)-MLPA (Multiplex ligation-dependent probe amplification) we have identified a maternally inherited large deletion of the ICR1 region in a patient and his mother. The deletion results in a variable clinical expression with a classical BWS in the mother and a more severe presentation of BWS in her son. By genome-wide SNP array analysis the deletion was found to span ~100 kb genomic DNA including the ICR1DMR, H19, two adjacent non-imprinted genes and two of three predicted enhancer elements downstream to H19. Methylation analysis by deep bisulfite next generation sequencing revealed hypermethylation of the maternal allele at the IGF2 locus in both, mother and child, although IGF2 is not affected by the deletion.

Conclusions

We here report on a novel large familial deletion of the ICR1 region in a BWS family. Due to the deletion of the ICR1-DMR CTCF binding cannot take place and the residual enhancer elements have access to the IGF2 promoters. The aberrant methylation (hypermethylation) of the maternal IGF2 allele in both affected family members may reflect the active state of the normally silenced maternal IGF2 copy and can be a consequence of the deletion. The deletion results in a variable clinical phenotype and expression.

【 授权许可】

   
2015 Fryssira et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Beckwith J. Extreme cytomegaly of the adrenal fetal cortex, hyperplasia of kidneys and pancreas, and Leydig-cell hyperplasia. Another syndrome? [Abstract]. Western Society for Pediatric research: 11 November 1963, Los Angeles 1963
• [2]Wiedemann HR: [Familial malformation complex with umbilical hernia and macroglossia--a “New syndrome”?]. J Genet Hum 1964, 13:223-32.
• [3]Weksberg R, Shuman C, Beckwith JB: Beckwith-Wiedemann syndrome. Eur J Hum Genet 2010, 18:8-14.
• [4]Engel JR, Smallwood A, Harper A, Higgins MJ, Oshimura M, Reik W, et al.: Epigenotype-phenotype correlations in Beckwith-Wiedemann syndrome. J Med Genet 2000, 37:921-6.
• [5]Choufani S, Shuman C, Weksberg R: Beckwith-Wiedemann syndrome. Am J Med Genet C Semin Med Genet 2010, 154C:343-54.
• [6]Weksberg R, Shuman C, Smith AC: Beckwith-Wiedemann syndrome. Am J Med Genet C Semin Med Genet 2005, 137C:12-23.
• [7]Horsthemke B: Mechanisms of imprint dysregulation. Am J Med Genet C Semin Med Genet 2010, 154C:321-8.
• [8]Maher ER, Reik W: Beckwith-Wiedemann syndrome: imprinting in clusters revisited. J Clin Invest 2000, 105:247-52.
• [9]Choufani S, Shuman C, Weksberg R: Molecular findings in Beckwith-Wiedemann syndrome. Am J Med Genet C Semin Med Genet 2013, 163C:131-40.
• [10]Niemitz EL, DeBaun MR, Fallon J, Murakami K, Kugoh H, Oshimura M, et al.: Microdeletion of LIT1 in familial Beckwith-Wiedemann syndrome. Am J Hum Genet 2004, 75:844-9.
• [11]Zollino M, Orteschi D, Marangi G, De Crescenzo A, Pecile V, Riccio A, et al.: A case of Beckwith-Wiedemann syndrome caused by a cryptic 11p15 deletion encompassing the centromeric imprinted domain of the BWS locus. J Med Genet 2010, 47:429-32.
• [12]Algar E, Dagar V, Sebaj M, Pachter N: An 11p15 imprinting centre region 2 deletion in a family with Beckwith Wiedemann syndrome provides insights into imprinting control at CDKN1C. PLoS One 2011., 6Article ID e29034
• [13]Gurrieri F, Zollino M, Oliva A, Pascali V, Orteschi D, Pietrobono R, et al.: Mild Beckwith-Wiedemann and severe long-QT syndrome due to deletion of the imprinting center 2 on chromosome 11p. Eur J Hum Genet 2013, 21:965-9.
• [14]Sparago A, Cerrato F, Vernucci M, Ferrero GB, Silengo MC, Riccio A: Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith-Wiedemann syndrome. Nat Genet 2004, 36:958-60.
• [15]Sparago A, Russo S, Cerrato F, Ferraiuolo S, Castorina P, Selicorni A, et al.: Mechanisms causing imprinting defects in familial Beckwith-Wiedemann syndrome with Wilms’ tumour. Hum Mol Genet 2007, 16:254-64.
• [16]Demars J, Shmela ME, Rossignol S, Okabe J, Netchine I, Azzi S, et al.: Analysis of the IGF2/H19 imprinting control region uncovers new genetic defects, including mutations of OCT-binding sequences, in patients with 11p15 fetal growth disorders. Hum Mol Genet 2010, 19:803-14.
• [17]De Crescenzo A, Coppola F, Falco P, Bernardo I, Ausanio G, Cerrato F, et al.: A novel microdeletion in the IGF2/H19 imprinting centre region defines a recurrent mutation mechanism in familial Beckwith-Wiedemann syndrome. Eur J Med Genet 2011, 54:e451-4.
• [18]Demars J, Rossignol S, Netchine I, Lee KS, Shmela M, Faivre L, et al.: New insights into the pathogenesis of Beckwith-Wiedemann and Silver-Russell syndromes: contribution of small copy number variations to 11p15 imprinting defects. Hum Mutat 2011, 32:1171-82.
• [19]Baskin B, Choufani S, Chen YA, Shuman C, Parkinson N, Lemyre E, et al.: High frequency of copy number variations (CNVs) in the chromosome 11p15 region in patients with Beckwith-Wiedemann syndrome. Hum Genet 2014, 133:321-30.
• [20]Prawitt D, Enklaar T, Gartner-Rupprecht B, Spangenberg C, Oswald M, Lausch E, et al.: Microdeletion of target sites for insulator protein CTCF in a chromosome 11p15 imprinting center in Beckwith-Wiedemann syndrome and Wilms’ tumor. Proc Natl Acad Sci U S A 2005, 102:4085-90.
• [21]Beygo J, Citro V, Sparago A, De Crescenzo A, Cerrato F, Heitmann M, et al.: The molecular function and clinical phenotype of partial deletions of the IGF2/H19 imprinting control region depends on the spatial arrangement of the remaining CTCF-binding sites. Hum Mol Genet 2013, 22:544-57.
• [22]Murphy R, Baptista J, Holly J, Umpleby AM, Ellard S, Harries LW, et al.: Severe intrauterine growth retardation and atypical diabetes associated with a translocation breakpoint disrupting regulation of the insulin-like growth factor 2 gene. J Clin Endocrinol Metab 2008, 93:4373-80.
• [23]Gronskov K, Poole RL, Hahnemann JM, Thomson J, Tumer Z, Brondum-Nielsen K, et al.: Deletions and rearrangements of the H19/IGF2 enhancer region in patients with Silver-Russell syndrome and growth retardation. J Med Genet 2011, 48:308-11.
• [24]Berland S, Appelback M, Bruland O, Beygo J, Buiting K, Mackay DJ, et al.: Evidence for anticipation in Beckwith-Wiedemann syndrome. Eur J Hum Genet 2013, 21:1344-8.
• [25]Rahmann S, Beygo J, Kanber D, Martin M, Horsthemke B, Buiting K. Amplikyzer: Automated methylation analysis of amplicons from bisulfite flowgram sequencing. PeerJ PrePrints 1:e122v2 http://www.dxdoiorg/107287/peerjpreprints122v2 2013.
• [26]Frazer KA, Pachter L, Poliakov A, Rubin EM, Dubchak I: VISTA: computational tools for comparative genomics. Nucleic Acids Res 2004, 32:W273-9.
• [27]Blanchette M, Kent WJ, Riemer C, Elnitski L, Smit AF, Roskin KM, et al.: Aligning multiple genomic sequences with the threaded blockset aligner. Genome Res 2004, 14:708-15.
• [28]Cerrato F, De Crescenzo A, Riccio A: Looking for CDKN1C enhancers. Eur J Hum Genet 2014, 22:442-3.
• [29]Arney KL: H19 and Igf2–enhancing the confusion? Trends Genet 2003, 19:17-23.
• [30]ENCODE Project Consortium: An integrated encyclopedia of DNA elements in the human genome Nature 2012, 489:57-74.
• [31]Murrell A, Ito Y, Verde G, Huddleston J, Woodfine K, Silengo MC, et al.: Distinct methylation changes at the IGF2-H19 locus in congenital growth disorders and cancer. PLoS One 2008., 3Article ID e1849
• [32]Zubair M, Hilton K, Saam JR, Surani MA, Tilghman SM, Sasaki H: Structure and expression of the mouse L23mrp gene downstream of the imprinted H19 gene: biallelic expression and lack of interaction with the H19 enhancers. Genomics 1997, 45:290-6.
• [33]Riccio A, Sparago A, Verde G, De Crescenzo A, Citro V, Cubellis MV, et al.: Inherited and Sporadic Epimutations at the IGF2-H19 locus in Beckwith-Wiedemann syndrome and Wilms’ tumor. Endocr Dev 2009, 14:1-9.
• [34]Wu L, Wang L, Shangguan S, Chang S, Wang Z, Lu X, et al.: Altered methylation of IGF2 DMR0 is associated with neural tube defects. Mol Cell Biochem 2013, 380:33-42.